Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.
Anthropocene Magazine13h
Increased access to medications may be a public health good—but it’s a big climate challenge
A massive global analysis reveals pharmaceuticals as the most carbon-intensive portion of the global health care system ...
Becker's Hospital Review1d
Physician Advisor Programs of the Future Call for Innovation and Flexible Support Models
Amidst inflation, rising costs of providing care, and staffing shortages, the role of Physician Advisors (PAs) is poised to become increasingly critical. That’s because Physician Advisors play a vital ...
Le Lézard1d
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
BioLineRx Ltd. , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December ...
Altria: Smoke-Free Ambitions On Hold (Rating Downgrade)
Altria faces challenges in the vape market and valuation pressure, but its 7% dividend yield and tariff insulation offer ...
Shenzhen JPT Opto-Electronics And 2 Other High Growth Tech Stocks In Asia
As global markets grapple with fluctuating economic indicators and policy uncertainties, Asian tech stocks have shown resilience amid mixed performances across major indices. In this context, ...